Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Recursion Pharmaceuticals
ISIN US75629V1044
|WKN A3CM1C
Market cap (in EUR)
1,530 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 1,530 m |
| EPS, EUR | -1.04 |
| P/B ratio | 1.7 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 66 m |
| Net income, EUR | -572 m |
| Profit margin | -863.35% |
What ETF is Recursion Pharmaceuticals in?
There are 37 ETFs which contain Recursion Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Recursion Pharmaceuticals is the ARK Genomic Revolution UCITS ETF USD Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.